Lenalidomide G.L.

Lenalidomide, the active ingredient in Lenalidomide G.L., is an immunomodulatory drug presented as an oral tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide G.L. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma or lymphoid cells.

- Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients. - Myelodysplastic Syndromes: reduces transfusion dependence and delays progression to acute leukemia. - Mantle Cell Lymphoma: contributes to disease control in relapsed or refractory settings.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Neutropenia: reduced neutrophil counts increasing infection risk. - Diarrhea: loose stools that may affect hydration. - Nausea: feeling of sickness often occurring after dosing.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: markedly low neutrophil levels requiring medical intervention. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease. - Hepatic injury: significant liver enzyme elevations or failure.

Before initiating therapy, clinicians should evaluate several safety considerations.

- Monitor blood counts: perform regular CBCs to detect cytopenias. - Assess thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients. - Avoid in pregnancy: teratogenic; ensure effective contraception. - Adjust for renal impairment: dose modifications may be needed based on creatinine clearance. - Contraception required: both male and female patients must use reliable methods. - Store at room temperature: keep in the original pack, protect from moisture and light.

Lenalidomide can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: heightened infection risk due to immunomodulation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise lenalidomide levels. - NSAIDs: additive risk of thrombocytopenia. - Digoxin: possible alteration of serum concentrations.